Overview of ROSA NSG experiments
| . | Cells injected × 106 . | BM engraftment (positive/total)* . | Median engraftment of intravenously injected mice (%) . | Subcutaneous tumor growth (positive/total)† . |
|---|---|---|---|---|
| ROSAKIT WT | 5 | 4/5 (18 wk) | 2.62 | 1/5 |
| ROSAKIT D816V | 0.4 | 4/4 (21 wk) | 52 | 1/4 |
| . | Cells injected × 106 . | BM engraftment (positive/total)* . | Median engraftment of intravenously injected mice (%) . | Subcutaneous tumor growth (positive/total)† . |
|---|---|---|---|---|
| ROSAKIT WT | 5 | 4/5 (18 wk) | 2.62 | 1/5 |
| ROSAKIT D816V | 0.4 | 4/4 (21 wk) | 52 | 1/4 |
Table shows engraftment of ROSAKIT WT and of ROSAKIT D816V cells in NSG mice. Percentage of engrafted human MCs was assessed by flow cytometry using their double positivity for human CD45 and human CD117 antigens.
Number of mice showing an engraftment of ROSA cells >0.1% in bone marrow after intravenous injection of total mice injected that survived more than 12 weeks.
Number of mice showing a subcutaneous tumor formation after subcutaneous injection of total mice injected (2 sites per mouse) that survived more than 12 weeks.